The Fed came very close to promising a rate cut Wednesday, and now markets are focused on a possible July rate cut.Market Insiderread more
Markets had expected the central bank to keep its benchmark interest rate steady while setting up a cut at the July meeting.The Fedread more
Powell said policymakers are concerned about some of the recent economic developments and see a growing case for easier policy.The Fedread more
The Fed chief said that despite reports that Trump was looking to demote or fire him, he doesn't plan on leaving anytime soon.The Fedread more
With bold and targeted steps, economists say, government can increase opportunity and incomes for many more people in ways that strengthen, not weaken, American capitalism.Politicsread more
Slack Technologies' reference price was set at $26 per share, the New York Stock Exchange announced Wednesday evening.Technologyread more
If the Trump administration and Congress fail to reach a spending agreement, the White House will offer to keep the government funded at its current levels for a year, Mnuchin...Politicsread more
Resident "Fast Money" crypto expert Brian Kelly breaks down the major differences between bitcoin and Facebook's new cryptocurrency Libra.Fast Moneyread more
Oracle found revenue growth from cloud applications in its fiscal fourth quarter, which helped it surpass analysts' expectations.Technologyread more
Federal Reserve Chairman Jerome Powell said on Wednesday that Facebook spoke to the central bank about the digital currency called LibraThe Fedread more
The vote makes Mexico the first of the three countries to win legislative approval for the trade agreement.Politicsread more
Patients with private health insurance will soon be able to get HIV prevention medication, also known as pre-exposure prophylaxis or PrEP, at no cost after a recommendation from an influential health-care panel Tuesday.
The U.S. Preventive Services Task Force gave PrEP a grade A recommendation, meaning insurers will now be obligated to cover the medication at no cost to their policyholders. Under the Affordable Care Act, more commonly known as Obamacare, private health plans are required to cover preventative services that the task force grants an "A" or "B" rating.
The recommendation was published Tuesday in the Journal of the American Medical Association. The task force, which is made up of an independent panel of clinicians and scientists, said it found convincing evidence that PrEP is of "substantial benefit in decreasing the risk of HIV infection."
The task force also proposed regular HIV screening for pregnant women and individuals aged 15 to 65 years.
"The new guidelines show a maturation of evidence and policy in HIV medicine and a growing consensus affecting application, not only in the United States but worldwide," Dr. Hyman Scott, a professor of medicine at the University of California San Francisco, wrote in an editorial published Tuesday alongside the JAMA report. He is not a member of the task force.
Roughly 1.1 million people in the U.S. are currently living with HIV, and nearly 40,000 Americans become infected with the virus each year, according to government data. PrEP can reduce the risk of infection by up to 92% in people who are at high risk and who take the drug consistently, according to the Centers for Disease Control and Prevention.
The move comes amid President Donald Trump's pledge to end the HIV epidemic in the United States by 2030, a goal which public health advocates have cheered and have sought for years.
In May, pharmaceutical giant Gilead Sciences reached an agreement with the Trump administration to donate its PrEP medication Truvada for up to 200,000 uninsured people a year until 2025. Without insurance, Truvada usually sells for $1,600 to $2,000 a month in the U.S.